Safety and Performance of the Ultimaster Nagomi Stent for Long Coronary Lesions Using a One-Stent Approach
Led by Fundación EPIC · Updated on 2026-09-11
1039
Participants Needed
10
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing the use of the Ultimaster Nagomi stent in treating coronary artery disease, focusing on its safety and performance in real-world settings. This post-market clinical follow-up study aims to reaffirm the devices effectiveness and safety claims without comparing it to other treatments.
Participants treated with the Ultimaster Nagomi drug-eluting stent DES will be followed according to standard hospital practice. The study includes patients with long coronary lesions suitable for a one-stent approach, and all treated lesions are intended to receive this stent. No comparator group is involved as the study observes routine clinical use.
During the study, participants undergo assessments including angina status using the Seattle Angina Questionnaire and quality of life via the EuroQol five-dimensional questionnaire at baseline and 12 months. Researchers will track device and procedure safety, performance in complex lesions, and clinical outcomes like target lesion failure, cardiovascular death, and myocardial infarction over one year. The total study duration extends until 2029, with ongoing data collection and monitoring.
CONDITIONS
Brief Title
LONG NAGOMI™ PMCF STUDY
Research Team
T
TAMARA GARCIA CAMARERO, MD, PhD
F
FUNDACION EPIC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients suitable for PCI according to European clinical practice guidelines
Patients with at least one long coronary lesion fit for a single stent approach
Patients who have provided written informed consent after being informed about the study
Intention to treat all lesions with the Ultimaster Nagomi stent
You will not qualify if you...
Patients who decline to participate
Pregnant or breastfeeding women
Patients with acute coronary syndrome under cardiogenic shock (Killip class 4)
Patients with contraindications or hypersensitivity to sirolimus
Patients with life expectancy less than 2 years
Patients planning surgery requiring general anesthesia or likely to need early discontinuation of dual anti-platelet therapy
Patients enrolled in other clinical trials without achieving primary objectives
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 1 year
Participants receive the Ultimaster Nagomi stent as part of their standard care for coronary artery disease involving long lesions suitable for a single stent.
Follow-up visits at baseline and 12 months with questionnaires and clinical assessments
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Evaluating Myocardial Viability in Ischemic Heart Disease Using Integrated 18F-FDG PETMR Imaging Before Surgery
Study of Implantable Cardioverter Defibrillator Benefits in Adults with Coronary Artery Disease and Ventricular Fibrillation After Complete Revascularization
Evaluating a New Cardiac Rehabilitation Approach for Adults With Ischemic Heart Disease
A Prospective, Randomized Controlled Study Comparing New and Traditional Therapies
Randomized Double-Blind Study Evaluating Intravenous YN001 Versus Placebo in Adults With Coronary Atherosclerosis Receiving Cardiovascular Risk Therapy
Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure
Real-World Registry of Quantitative Flow Ratio-Guided Coronary Revascularization and Quality Evaluation Across Multiple Centers in China
Evaluating Coronary CT Angiography to Guide Calcium Modification Compared to Intravascular Ultrasound in Treating Calcified Coronary Artery Disease A Multicenter Randomized Trial
Study on Ultrasound Screening and Combined Treatments for Patients With Coronary and Head and Neck Artery Narrowing
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
One-Year Outcomes of Long Coronary Drug-Eluting Stents (≥40 MM) in Patients With Diffuse Coronary Artery Disease: Findings From a Tertiary Care Hospital in North India.